Study of Thymidylate Synthase (TS) and Dihydropyrimidine Dehydrogenase (DPD) Expressions on 5-Fluorouracil in Oral Squamous Cell Carcinoma

Khaleda, Akhter; Rashid, Mohammed Enamur

doi:10.31557/apjcp.2019.20.2.503

Cited by 4 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, the inhibition of tumoral dihydropyrimidine dehydrogenase increased the sensitivity threshold of cancer cells to this medication. 29 Gao et al 30 evaluated mRNA expression by the cancer cells in 399 patients with HNSCC and showed that high expression of interleukin 6 was associated with poor prognosis and chemical resistance in many cancer cells, without requiring any mediator.…”

Section: Discussionmentioning

confidence: 99%

Drug resistance against 5-fluorouracil and cisplatin in the treatment of head and neck squamous cell carcinoma: A systematic review

Atashi

Vahed

Emamverdizadeh

et al. 2021

J Dent Res Dent Clin Dent Prospects

View full text Add to dashboard Cite

Head and neck cancers are highly prevalent worldwide. Most of these lesions are diagnosed in the advanced stages of the disease. Thus, they do not often have a good long-term prognosis. Like other cancer types, head and neck cancers are managed by surgery, radiotherapy, and chemotherapy. Despite significant advances in the treatment of oral squamous cell carcinoma (OSCC), physicians encounter several challenges in the course of treatment. Various mechanisms mediate the clinical responses of a certain cancer to medications. Thus, efficient treatment planning requires adequate knowledge about the genes involved in drug resistance and the evaluation of the frequency percentage of resistance. Several studies have evaluated the causes and frequency percentages of 5-fluorouracil (5-FU) and cisplatin resistance. In this systematic review, all the relevant articles published until November 30, 2019, were retrieved from the Scopus, Embase, Medline, ISI, Web of Science, and Cochrane databases using certain MeSH and EMTTree keywords. A total of 2164 articles were retrieved of which, 18 were included in the review since they had reported the frequency percentages of drug resistance. Of all, 10 articles had evaluated cisplatin (1317 samples). A meta-analysis of the results revealed a frequency of 33% for cisplatin resistance. Eight studies had evaluated 5-FU (476 samples). A meta-analysis of the results revealed a frequency of 40.2 % for 5-FU resistance. Overcoming cisplatin resistance or 5-FU resistance can significantly enhance recovery in advanced HNSCC. Attempts should be made to eliminate the cause and use multi-drug regimens to increase the success rate of treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug resistance against 5-fluorouracil and cisplatin in the treatment of head and neck squamous cell carcinoma: A systematic review

Atashi

Vahed

Emamverdizadeh

et al. 2021

J Dent Res Dent Clin Dent Prospects

View full text Add to dashboard Cite

show abstract

“…Mitochondrial methylenetetrahydrofolate dehydrogenase 2 and its downstream purine synthesis pathway played an important role in the chemoresistance of lung cancer cells to gefitinib [94]. Akhter et al reported that over-expression of intratumoral thymidylate synthase significantly contributed to the resistance while suppression of dihydropyrimidine dehydrogenase enhanced the sensitivity of 5-FU treatment in oral squamous cell carcinoma [95]. Nicotinamide phosphoribosyltransferase (NAMPT) is an important enzyme for tumor nicotinamide metabolism, which catalyzes the biosynthesis of nicotinamide adenine dinucleotide.…”

Section: Nucleotide Metabolismmentioning

confidence: 99%

Targeting Cancer Metabolism to Resensitize Chemotherapy: Potential Development of Cancer Chemosensitizers from Traditional Chinese Medicines

Guo

Tan

Chen

et al. 2020

Cancers

View full text Add to dashboard Cite

Cancer is a common and complex disease with high incidence and mortality rates, which causes a severe public health problem worldwide. As one of the standard therapeutic approaches for cancer therapy, the prognosis and outcome of chemotherapy are still far from satisfactory due to the severe side effects and increasingly acquired resistance. The development of novel and effective treatment strategies to overcome chemoresistance is urgent for cancer therapy. Metabolic reprogramming is one of the hallmarks of cancer. Cancer cells could rewire metabolic pathways to facilitate tumorigenesis, tumor progression, and metastasis, as well as chemoresistance. The metabolic reprogramming may serve as a promising therapeutic strategy and rekindle the research enthusiasm for overcoming chemoresistance. This review focuses on emerging mechanisms underlying rewired metabolic pathways for cancer chemoresistance in terms of glucose and energy, lipid, amino acid, and nucleotide metabolisms, as well as other related metabolisms. In particular, we highlight the potential of traditional Chinese medicine as a chemosensitizer for cancer chemotherapy from the metabolic perspective. The perspectives of metabolic targeting to chemoresistance are also discussed. In conclusion, the elucidation of the underlying metabolic reprogramming mechanisms by which cancer cells develop chemoresistance and traditional Chinese medicines resensitize chemotherapy would provide us a new insight into developing promising therapeutics and scientific evidence for clinical use of traditional Chinese medicine as a chemosensitizer for cancer therapy.

show abstract

“…Various Phase III trials observed that participants with nonsquamous NSCLC had better response rates with pemetrexed compared to those with other histologic subtypes (36)(37)(38). Such an observation has been explained by the presence of thymidylate synthase (TS) which is expressed in SCC (39). However, the mechanism by which the expression of TS influences response to pemetrexed is not yet well understood.…”

Section: Introduction Of New Treatments Based On Histological Charact...mentioning

confidence: 99%

The Emerging Roles of Histology in the Management of Lung Cancer

Alsuhaymi¹

2022

PJMHS

View full text Add to dashboard Cite

For many years, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) have been treated as single-disease entities. However, there are significant histologic and molecular differences between the various types of lung cancers. Such differences influence the various chemotherapeutic agents' outcomes and side effect profiles. For instance, bevacizumab causes significant pulmonary hemorrhage in squamous cell carcinoma; hence it is not recommended to treat such histologic subtypes. SCLC is more aggressive than NSCLC; therefore, it demonstrates differences in tumor behavior and the need to approach treatments differently. To date, studies of various lung cancers have provided new insight into their molecular characteristics. The histological classification does not only focus on the morphology but can provide detailed histological characteristics that will promote targeted therapy. Can this new knowledge assist in developing more effective drugs for lung cancers? In this paper, the review shows the advancements in histological diagnosis of lung cancers and their use in the optimal treatment of lung cancers. Keywords: Small cell lung cancer, non-small cell lung cancer, histological subtypes.

show abstract

Study of Thymidylate Synthase (TS) and Dihydropyrimidine Dehydrogenase (DPD) Expressions on 5-Fluorouracil in Oral Squamous Cell Carcinoma

Cited by 4 publications

References 22 publications

Drug resistance against 5-fluorouracil and cisplatin in the treatment of head and neck squamous cell carcinoma: A systematic review

Drug resistance against 5-fluorouracil and cisplatin in the treatment of head and neck squamous cell carcinoma: A systematic review

Targeting Cancer Metabolism to Resensitize Chemotherapy: Potential Development of Cancer Chemosensitizers from Traditional Chinese Medicines

The Emerging Roles of Histology in the Management of Lung Cancer

Contact Info

Product

Resources

About